Amplia Therapeutics Showcases Cancer Drug Progress

Amplia Therapeutics Ltd. (AU:ATX) has released an update.

Amplia Therapeutics Ltd. has announced the inclusion of data from their ACCENT trial on narmafotinib in advanced pancreatic cancer at the ASCO annual meeting, highlighting the drug’s tolerability and preliminary efficacy. The Phase 1b results showed a positive partial response in patients and identified an optimal dose for ongoing Phase 2a trials. The company aims to enhance narmafotinib’s visibility to potential partners and oncologists through this significant conference.

For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.